markets is the sole category represented across all 1 tracked stories. Cushman & Wakefield is most often covered alongside European Life Sciences Coalition, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 4.7 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Cushman & Wakefield
markets is the sole category represented across all 1 tracked stories. Cushman & Wakefield is most often covered alongside European Life Sciences Coalition, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 4.7 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.7. Cushman & Wakefield appears in 1 tracked Finance story from February 18, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 90 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Cushman & Wakefield. Shared-story counts are live from our verified record — not editorial picks.
Leading European venture capital firms have launched the European Life Sciences Coalition to address a systemic funding crisis and prevent the migration of high-growth biotech firms to U.S. markets. The initiative seeks to unlock institutional capital and harmonize regulations to bridge the late-stage investment gap between Europe and North America.